Company intelligence / Profile preview
Kodiak Biosciences
Palo Alto, California, United Stateskodiak.com ↗
- Ownership
- Public · KOD
- Employees
- ~109
- Development stage
- Phase 3
01
Overview
Kodiak Sciences’ lead candidate, tarcocimab tedromer, has advanced through multiple Phase 3 trials targeting high-prevalence retinal vascular diseases such as wet AMD, diabetic retinopathy, and retinal vein occlusion. KSI‑501 is in late-stage development for similar indications with a dual mechanism of action. The company’s pipeline also includes earlier-stage assets addressing both neovascular and inflammatory components of ocular disease.
- Therapeutic areas
- Ophthalmology
- Modalities
- Antibody biopolymer conjugatesBispecific antibodiesProtein therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Nona Biosciences – collaboration on multi-target antibody discovery announced December 2024Lonza Group – manufacturing partnership with new facility opened in Visp, Switzerland in May 2022
04
Financials
- Market cap
- $5.7B
- Total revenue
- $0
- Enterprise value
- $5.7B
Beyond the preview
Go deeper on Kodiak Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kodiak Biosciences.